Compile Data Set for Download or QSAR
Report error Found 85 Enz. Inhib. hit(s) with all data for entry = 8647
TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410295(US10370388, Compound Angiotensin)
Affinity DataKi:  0.898nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410295(US10370388, Compound Angiotensin)
Affinity DataIC50: 1.80nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410289(US10370388, Compound 138)
Affinity DataIC50: 3.52nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318822(US9624243, Losartin | US10370388, Compound Losarti...)
Affinity DataKi:  5.5nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318822(US9624243, Losartin | US10370388, Compound Losarti...)
Affinity DataIC50: 11nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318782((2S,4S)-1-(2,2-diphenylacetyl)-4-((3-(4-fluorophen...)
Affinity DataIC50: 12nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410270(US10370388, Compound 114)
Affinity DataIC50: 17.1nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318790((2S,4S)-1-(2,2-diphenylacetyl)-4-(5-phenyl-1H-1,2,...)
Affinity DataIC50: 18nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318810(US9624243, 126 | (2S,4S)-1-(2,2-diphenylacetyl)-4-...)
Affinity DataIC50: 20.5nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410246(US10370388, Compound 87)
Affinity DataIC50: 43.6nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318761( (2S,4S)-4-(3-benzylpiperidin-1-yl)-1-(2,2-dipheny...)
Affinity DataIC50: 43.9nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318773( (2S,4S)-4-(2-benzylpiperidin-1-yl)-1-(2,2-dipheny...)
Affinity DataIC50: 49.1nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410222(US10370388, Compound 51)
Affinity DataIC50: 50.3nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410208(US10370388, Compound 15)
Affinity DataIC50: 54.5nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318806(US9624243, 121 | (2S,4S)-4-((benzylthio)methyl)-1-...)
Affinity DataIC50: 57.7nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318758((2S,4S)-1-(2,2-diphenylacetyl)-4-((R)-3-phenylpipe...)
Affinity DataIC50: 58.8nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318750((2S,4S)-1-(2,2-diphenylacetyl)-4-(methyl(3-phenylp...)
Affinity DataIC50: 62.1nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410271(US10370388, Compound 52)
Affinity DataIC50: 63.2nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318781((2S,4S)-1-(2,2-diphenylacetyl)-4-(methyl(4-phenylb...)
Affinity DataIC50: 64.2nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318760(US9624243, 51 | US10370388, Compound 50)
Affinity DataIC50: 67.3nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410240(US10370388, Compound 84)
Affinity DataIC50: 75.8nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410229(US10370388, Compound 61-B | US10370388, Compound 6...)
Affinity DataIC50: 83.3nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318753((2S,4S)-4-((S)-3-benzylmorpholino)-1-(2,2-diphenyl...)
Affinity DataIC50: 86.9nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318815(US9624243, 136 | (2S,4S)-1-(2,2-diphenylacetyl)-44...)
Affinity DataIC50: 89nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410219(US10370388, Compound 48)
Affinity DataIC50: 89.4nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318744((2S,4S)-4-cinnamyloxy-1-(2,2-diphenylacetyl)pyrrol...)
Affinity DataIC50: 90nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318746( (2S,4R)-1-(2,2-diphenylacetyl)-4-(3-phenylpropoxy...)
Affinity DataIC50: 98.6nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410243(US10370388, Compound 85)
Affinity DataIC50: 103nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410229(US10370388, Compound 61-B | US10370388, Compound 6...)
Affinity DataIC50: 107nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318742((2S,4S)-4-(benzyloxy)-1-(2,2-diphenylacetyl)pyrrol...)
Affinity DataIC50: 114nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318784((2S,4S)-1-(2,2-diphenylacetyl)-4-(methyl(3-pyridin...)
Affinity DataIC50: 126nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318783((2S,4S)-1-(2,2-diphenylacetyl)-4-((3-(4-methoxy-3-...)
Affinity DataIC50: 134nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318807(US9624243, 122 | (2S,4S)-1-(2,2-diphenylacetyl)-4-...)
Affinity DataIC50: 143nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410224(US10370388, Compound 54)
Affinity DataIC50: 155nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318816(US9624243, 137 | (2S,4S)-1-(2,2diphenylacetyl)-4&#...)
Affinity DataIC50: 173nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318745(Compound 9 (2S,4R)-1-(2,2-diphenylacetyl)-4-(3-phe...)
Affinity DataIC50: 181nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318743((2S,4R)-4-(benzyloxy)-1-(2,2-diphenylacetyl)pyrrol...)
Affinity DataIC50: 193nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318788((2S,4S)-1-(2,2-diphenylacetyl)-4-(N-3-phenylpropyl...)
Affinity DataIC50: 240nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318814(US9624243, 135 | (2S,4S)-1-(2,2-diphenylacetyl)-N-...)
Affinity DataIC50: 240nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318759((2S,4S)—N—(N,N-dimethylsulfamoyl)-1-(2,2...)
Affinity DataIC50: 255nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410214(US10370388, Compound 23)
Affinity DataIC50: 290nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318803(US9624243, 118 | (2S,4S)-4-((benzylsulfonyl)methyl...)
Affinity DataIC50: 314nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM410226(US10370388, Compound 56)
Affinity DataIC50: 316nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318801(US9624243, 115 | (2S,4S)-4-(6-benzyl-7-oxa-2,6-di...)
Affinity DataIC50: 321nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318808(US9624243, 124 | (2S,4S)-1-(2,2-diphenylacetyl)-4-...)
Affinity DataIC50: 363nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318764(1-((2R,3S)-2-(hydroxymethyl)-3-(3-phenylpropoxy)-a...)
Affinity DataIC50: 372nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318751((2S,4S)-1-(2,2-diphenylacetyl)-4-(methyl(phenyleth...)
Affinity DataIC50: 384nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318763((2S,4R)-4-(2-(benzyloxy)ethyl)-1-(2,2-diphenylacet...)
Affinity DataIC50: 386nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318791((2S,4S)-4-(5-benzyl-1H-1,2,3-triazol-1-yl)-1-(2,2-...)
Affinity DataIC50: 400nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

TargetType-2 angiotensin II receptor(Human)
Novartis

US Patent
LigandPNGBDBM318795( (2S,4S)-1-(2,2-diphenylacetyl)-4-(4-phenylbutyl)-...)
Affinity DataIC50: 426nMAssay Description: 120 μL membrane (5 mg protein/well) was incubated with 15 μL of [125I]-CGP42112A and 15 μL of compound at RT for 1.5 hrs. The binding...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/6/2020
Entry Details
US Patent

Displayed 1 to 50 (of 85 total ) | Next | Last >>
Jump to: